Navigation Links
Onyx Pharmaceuticals Announces December 2010 Investor Events
Date:11/18/2010

EMERYVILLE, Calif., Nov. 18, 2010 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December:

ASH Briefing

December 7, 2010 – 10:00 a.m. ET

Investigators will discuss data presentations surrounding carfilzomib in relapsed and/or refractory multiple myeloma, as featured at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida.  The teleconference will begin at 10:00 a.m. ET on December 7, 2010.  The live webcast will be available at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-585-4405 and using the passcode 28465587.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 28465587# later in the day.  The replay will be available on the Onyx website through December 21, 2010.

Analyst Briefing on Development Program

December 14, 2010 – 8:30 a.m. ET

Onyx management will host an overview of its development program on December 14, 2010 at 8:30 a.m. ET.  The program will feature presentations on multiple tumor types by external clinical investigators and members of management.  Subsequent to the prepared remarks, the company will conduct a Q&A session with panelists and members of the management team. A replay of the webcast will be available through December 28, 2010.

The live webcast will be available at:

http://investor.shareholder.com/media/eventdetail.cfm?eventid=88245&CompanyID=ABEA-3ZQWBY&e=1&mediaKey=4A4EC5744A1EE0C2C6BAA4371A3F2CE4

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo Pharmaceuticals Holdings Inc. Announces Pricing of Private Offering of Senior Notes
2. Prolong Pharmaceuticals Boosts Executive Team
3. Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection
4. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
5. Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provids Unique MS Drug Candidate
6. Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
7. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
9. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
10. Vanda Pharmaceuticals Appoints Chief Financial Officer
11. Jazz Pharmaceuticals Announces Presentation at the Lazard Capital Markets Healthcare Conference on November 17
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  SARES•REGIS Group leased the first ... at Conejo Spectrum Business Park in ... Biotherapeutics, Inc. , a biopharmaceutical company developing meaningful ... that have been underserved by scientific innovation, with ... cancer, autoimmune and infectious disease. Before ...
(Date:4/18/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 6.35% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College is introducing enhancements ... their careers. Beginning in the fall of 2017, Emmanuel’s program will allow registered nurses ... as 16 months and for as little as $14,528. These changes will enable nurses ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Michael Vick announced ... transforming the quarterback position. The former overall number one pick in the 2001 NFL ... career. He holds the record for the most career rushing yards by a quarterback ...
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a ... new strategies to reduce waste, and support renewable energy. They believe this is a ... nature to find solutions for health issues, and maintain that destroying the environment in ...
(Date:4/24/2017)... Boulder, CO (PRWEB) , ... April 24, 2017 ... ... 2017 American Educational Research Association’s Outstanding Public Communication of Education Research Award. The ... the public, including education communities. It recognizes a scholar who has demonstrated the ...
(Date:4/24/2017)... ... ... Bright Pink , a national non-profit organization focusing on the prevention and early detection of ... is proud to announce Katie Thiede as their new Chief Executive Officer. In January, founder ... of the Board and launched a national search to find a visionary new leader to ...
Breaking Medicine News(10 mins):